CARGO Therapeutics Discontinues FIRCE-1 Clinical Study and
1 day ago · CARGO discontinues the FIRCE-1 study, reducing workforce by 50% while advancing CRG-023 into Phase 1 trials. Quiver AI Summary. CARGO Therapeutics, Inc. announced the …
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi …
1 day ago · CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile …
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of
1 day ago · Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the …
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of
1 day ago · Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the …
Cargo Therapeutics to discontinue FIRCE-1 Phase 2 study of Firi-cel
1 day ago · Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the …
CARGO Therapeutics To Discontinue FIRCE-1 Study, Cut …
1 day ago · CARGO plans to present a detailed analysis of the FIRCE-1 Phase 2 study at an upcoming medical conference. The company made its debut on the Nasdaq Capital Market on …
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-
Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended …
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi ...
1 day ago · CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile …
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi …
Stocks Set to Open Mixed With All Eyes on Fed Rate Decision and Big Tech Earnings
CARGO Therapeutics Announces Phase 1 Clinical Study of
Jul 10, 2024 · Firicabtagene autoleucel (firi-cel) is CARGO's investigational cell therapy composed of autologous T-cells transduced with a lentiviral vector (m971-BBZ) expressing a CD22 …